(Q43029585)

12 November 2017

Strategy for the maximization of clinically relevant information from hepatitis C virus, RT-PCR quantification (English)

1 reference

12 November 2017

1 reference

6

1 reference

12 November 2017

Levis J

1

1 reference

12 November 2017

Kenny-Walsh E

2

1 reference

12 November 2017

O'Sullivan K

3

1 reference

12 November 2017

Horgan M

4

1 reference

12 November 2017

Whelton M

5

1 reference

12 November 2017

Fanning L

7

1 reference

12 November 2017

1 February 2001

1 reference

Journal of Clinical Virology

12 November 2017

1 reference

12 November 2017

20

1 reference

12 November 2017

3

1 reference

12 November 2017

163-171

1 reference

Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA.

12 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900177-3

7 January 2021

Development of a quantitative PCR assay for monitoring HCV viraemia levels in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900177-3

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900177-3

7 January 2021

Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900177-3

7 January 2021

Natural fluctuations of hepatitis C viral load in a homogeneous patient population: A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900177-3

7 January 2021

Impact of various handling and storage conditions on quantitative detection of hepatitis C virus RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900177-3

7 January 2021

Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by quantiplex HCV RNA assay versions 1 and 2, Roche Monitor assay, and an in-house limiting dilution method

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900177-3

7 January 2021

Comparison of HCV RNA levels by branched DNA probe assay and by competitive polymerase chain reaction to predict effectiveness of interferon treatment for patients with chronic hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900177-3

7 January 2021

Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900177-3

7 January 2021

The clinical utility of viral quantitation using molecular methods.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900177-3

7 January 2021

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900177-3

7 January 2021

Performance of the automated COBAS AMPLICOR system for the detection of hepatitis C virus RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900177-3

7 January 2021

Quantitative measurement of serum HCV RNA in patients with chronic hepatitis C: comparison between Amplicor HCV monitor system and branched DNA signal amplification assay.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900177-3

7 January 2021

A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900177-3

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900177-3

7 January 2021

Usefulness of HCV-RNA assays in efficacy evaluation of interferon treatment for chronic hepatitis C: Amplicor HCV assay and branched DNA probe assay

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900177-3

7 January 2021

Standardization of hepatitis C virus RNA quantification

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900177-3

7 January 2021

Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity?

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900177-3

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900177-3

7 January 2021

10.1016/S1386-6532(00)00177-3

Identifiers

DOI

1 reference

release_5iivrvt3izgyze26p36jtuc2tm

12 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5iivrvt3izgyze26p36jtuc2tm

24 November 2022

mapped directly with Wikidata item

1 reference